Scott Schliebner, SVP and Head of the Center for Rare Diseases at PRA Health Sciences, a global healthcare intelligence partner, discusses the launch of its Patient-Centric Trial Development Toolkit designed to mitigate risks that frequently occur in rare disease clinical trials and introduce and affirm new patient-centric practices that promote trial participation. He talks about the significance of the toolkit, the partners worked within its creation, and what PRA is doing to aid in diversifying clinical trials.
Scott Schliebner is a clinical strategist with a 25-year background in drug development focused on rare diseases, orphan drugs, and advanced therapeutics.
He develops innovative solutions and strategic considerations to help overcome the operational, logistical, and ethical challenges inherent to conducting research with rare disease patients. Mr Schliebner’s efforts are focused on patient-centered approaches to drug development; reducing the burden of clinical trial participation; and leveraging novel and disruptive technologies to bring new therapies to patients faster.
Committed to collaborative efforts to further drug development, Mr Schliebner also serves as the Co-Chair of Global Genes’ Corporate Alliance and has developed active partnerships with other rare disease patient-focused organizations, patient advocacy groups, drug development institutes, and academic research centers.
He holds a Master’s Degree in Public Health (MPH) from the University of Utah School of Medicine, and completed a Graduate Research Fellowship at The National Institutes of Health.